Holen Sie sich die Stockscreener-App
161.76
0.12%
0.19
Handel nachbörslich:
161.76
Schlusskurs vom Vortag:
$161.57
Offen:
$161.73
24-Stunden-Volumen:
468.86K
Relative Volume:
0.35
Marktkapitalisierung:
$22.56B
Einnahmen:
$1.53B
Nettoeinkommen (Verlust:
$-214.69M
KGV:
-91.91
EPS:
-1.76
Netto-Cashflow:
$-43.68M
1W Leistung:
-3.81%
1M Leistung:
+1.01%
6M Leistung:
-3.48%
1J Leistung:
+44.89%
1-Tages-Spanne:
$160.72
$163.17
1-Wochen-Bereich:
$158.00
$170.48
52-Wochen-Spanne:
$92.14
$183.00
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Vergleichen Sie NTRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
161.76 | 22.56B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
429.33 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.20 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
547.01 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.38 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.24 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Natera Approves Equity Plan Amendment at Annual Meeting - TipRanks
DNA Testing Market Size, Share, and Forecast 2025-2033: Key - openPR.com
Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Where are the Opportunities in (NTRA) - news.stocktradersdaily.com
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance
Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com
Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia
Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India
Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa
Natera's Signatera test to be covered under Medicare - MSN
Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus
Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus
Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com
Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha
Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com
Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus
Natera announces Medicare coverage for Signatera MRD assay - TipRanks
Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia
Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus
Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus
Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma
Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com
Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st
Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World
Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha
NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Natera Inc-Aktie (NTRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chapman Steven Leonard | CEO AND PRESIDENT |
Jul 01 '25 |
Sale |
166.53 |
5,343 |
889,778 |
173,728 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Jul 01 '25 |
Sale |
166.77 |
3,000 |
500,305 |
130,205 |
| Marcus Gail Boxer | Director |
Jul 01 '25 |
Option Exercise |
24.42 |
4,299 |
104,982 |
12,417 |
| Marcus Gail Boxer | Director |
Jul 01 '25 |
Sale |
167.36 |
4,299 |
719,491 |
8,118 |
0.73%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):